KLHL23 and cutaneous melanoma: Our results showed that high expression of KLHL23 was associated with a poor prognosis in patients with liver cancer (LIHC, P = 0.002), adrenocortical carcinoma (ACC, P = 0.003), Kidney renal papillary cell carcinoma (KIRP, P = 0.006), and skin cutaneous melanoma (SKCM, P = 0.025) (Figure 3A–3D).